KETs2026 reloaded

24 Sept 2026 | Germany

Project cooperationUpdated on 1 October 2026

Coordinator seeks partners: trustworthy, human-in-the-loop clinical AI for chronic neuroimmune disease (HORIZON-HLTH-2027-02-TOOL-01)

CEO & Founder at M Bio Technology Inc.

TOKYO, Japan

About

M Bio Technology (Tokyo, physician-led SME) is building a consortium as coordinator for HORIZON-HLTH-2027-02-TOOL-01 (two-stage RIA; stage-1 deadline 13 April 2027, 17:00 Brussels time). Japan is associated to Horizon Europe Pillar II, so Japanese entities are eligible for funding. We pitched in WS 3 (AI & ICT) at KETs2026 reloaded and are now in follow-up talks with partners we met there.

What we bring:

  • A new serological biomarker layer: antibody assay using chemically synthesised glycolipid antigens

  • A clinical AI architecture in which AI only drafts, rule-based checks run outside the LLM, and a physician signs off every output, with a full audit trail and pseudonymisation at the hospital edge (GDPR by design)

We are looking for:

  1. Clinical centres in EU Member States with paediatric ADEM/MS or MS cohorts and longitudinal brain MRI (highest priority)

  2. An AI research group applying established methods to brain MRI and clinical data, including bias, robustness and fairness evaluation

  3. Secure, federated health-data infrastructure

  4. AI safety assurance and security for LLM/agent systems

  5. Qualified e-signature and audit-trail services

  6. A European partner for proposal office and project management

Timeline: partner discussions October-December 2026; consortium and work-package split finalised by end of 2026; stage-1 proposal drafting January-April 2027.

Status: architecture and core tool definitions completed in 2026; prototype in build.

Online meetings (CEST): 5 Oct from 10:00, 20 Oct, 22 Oct, and later dates on request through the long-term matchmaking (until end of January 2027).

Similar opportunities